Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
GENESIS MAGMA RACING PREPARES FOR 24 HOURS OF LE MANS EXPERIENCE BOTH ON AND OFFTRACK
Genesis Magma Racing will have a presence at the 24 Hours of…
